This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
l-3,4-Dihydroxyphenylalanine (l-dopa)-induced dyskinesia affects virtually every patient with Parkinson disease (PD) after chronic administration.1 The pathophysiology of dyskinesia is complex, and several nondopaminergic systems are involved.2 The serotonin (5-HT) system has received much attention over the past years as a critical player underlying dyskinesia and as a potentially efficacious therapeutic target. 5-HT neurons contain the required enzymes to synthesize dopamine from l-dopa3 but without the regulatory mechanisms required for dopaminergic transmission, resulting in dysregulated, nonphysiologic dopamine release, which underlies the dyskinetic state.4 However, if this aberrant dopamine release by 5-HT fibers is the culprit in dyskinesia, it is also responsible, at least partly, for the antiparkinsonian action of l-dopa.5 As a result, it has proven difficult to achieve an antidyskinetic benefit with agonists of the 5-HT1A receptors, which act by dampening this aberrant dopamine release by 5-HT terminals, without hindering the therapeutic effect of l-dopa in both preclinical and clinical settings.6,7
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 853
- © 2015 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker